Annual EBITDA
-$81.40 M
-$27.02 M-49.69%
December 31, 2023
Summary
- As of March 1, 2025, LPTX annual EBITDA is -$81.40 million, with the most recent change of -$27.02 million (-49.69%) on December 31, 2023.
- During the last 3 years, LPTX annual EBITDA has fallen by -$53.96 million (-196.61%).
- LPTX annual EBITDA is now -1045.34% below its all-time high of -$7.11 million, reached on December 31, 2012.
Performance
LPTX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$18.35 M
+$2.44 M+11.75%
September 30, 2024
Summary
- As of March 1, 2025, LPTX quarterly EBITDA is -$18.35 million, with the most recent change of +$2.44 million (+11.75%) on September 30, 2024.
- Over the past year, LPTX quarterly EBITDA has dropped by -$8.04 million (-77.97%).
- LPTX quarterly EBITDA is now -346.30% below its all-time high of $7.45 million, reached on December 31, 2015.
Performance
LPTX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$64.04 M
-$4.08 M-6.80%
September 30, 2024
Summary
- As of March 1, 2025, LPTX TTM EBITDA is -$64.04 million, with the most recent change of -$4.08 million (-6.80%) on September 30, 2024.
- Over the past year, LPTX TTM EBITDA has increased by +$17.16 million (+21.14%).
- LPTX TTM EBITDA is now -3597.34% below its all-time high of -$1.73 million, reached on March 31, 2013.
Performance
LPTX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
LPTX EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -49.7% | -78.0% | +21.1% |
| 3 y3 years | -196.6% | +56.8% | +25.9% |
| 5 y5 years | -253.1% | +56.8% | +25.9% |
LPTX EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -100.8% | at low | -79.1% | +56.8% | -58.0% | +25.9% |
| 5 y | 5-year | -196.6% | at low | -182.2% | +56.8% | -134.9% | +25.9% |
| alltime | all time | -1045.3% | at low | -346.3% | +56.8% | -3597.3% | +25.9% |
Leap Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$18.35 M(-11.7%) | -$64.04 M(+6.8%) |
| Jun 2024 | - | -$20.80 M(+42.7%) | -$59.96 M(+12.5%) |
| Mar 2024 | - | -$14.57 M(+41.3%) | -$53.32 M(-34.3%) |
| Dec 2023 | -$81.40 M(+49.7%) | -$10.31 M(-27.8%) | -$81.20 M(-2.0%) |
| Sep 2023 | - | -$14.28 M(+0.9%) | -$82.83 M(-1.0%) |
| Jun 2023 | - | -$14.16 M(-66.6%) | -$83.64 M(-3.2%) |
| Mar 2023 | - | -$42.45 M(+255.3%) | -$86.38 M(+59.4%) |
| Dec 2022 | -$54.38 M(+34.1%) | -$11.95 M(-20.8%) | -$54.18 M(+2.2%) |
| Sep 2022 | - | -$15.08 M(-10.8%) | -$53.03 M(+8.1%) |
| Jun 2022 | - | -$16.90 M(+64.9%) | -$49.07 M(+17.8%) |
| Mar 2022 | - | -$10.25 M(-5.1%) | -$41.67 M(+2.8%) |
| Dec 2021 | -$40.54 M(+47.7%) | -$10.80 M(-2.9%) | -$40.54 M(+11.2%) |
| Sep 2021 | - | -$11.12 M(+17.0%) | -$36.45 M(+12.6%) |
| Jun 2021 | - | -$9.50 M(+4.3%) | -$32.35 M(+10.2%) |
| Mar 2021 | - | -$9.11 M(+35.9%) | -$29.36 M(+7.7%) |
| Dec 2020 | -$27.44 M(-16.4%) | -$6.71 M(-4.6%) | -$27.26 M(-4.5%) |
| Sep 2020 | - | -$7.03 M(+8.1%) | -$28.55 M(-2.4%) |
| Jun 2020 | - | -$6.50 M(-7.3%) | -$29.25 M(-5.4%) |
| Mar 2020 | - | -$7.02 M(-12.2%) | -$30.91 M(-4.3%) |
| Dec 2019 | -$32.83 M(+42.4%) | -$8.00 M(+3.4%) | -$32.30 M(+41.7%) |
| Sep 2019 | - | -$7.73 M(-5.3%) | -$22.79 M(+5.2%) |
| Jun 2019 | - | -$8.16 M(-2.9%) | -$21.67 M(+3.9%) |
| Mar 2019 | - | -$8.41 M(-655.7%) | -$20.85 M(-9.5%) |
| Dec 2018 | -$23.05 M | $1.51 M(-122.9%) | -$23.05 M(-25.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$6.62 M(-9.9%) | -$30.78 M(-0.5%) |
| Jun 2018 | - | -$7.34 M(-30.7%) | -$30.95 M(+1.4%) |
| Mar 2018 | - | -$10.60 M(+70.5%) | -$30.51 M(+4.6%) |
| Dec 2017 | -$29.19 M(+19.7%) | -$6.22 M(-8.3%) | -$29.18 M(+3.6%) |
| Sep 2017 | - | -$6.78 M(-1.8%) | -$28.17 M(-0.4%) |
| Jun 2017 | - | -$6.91 M(-25.5%) | -$28.27 M(-1.2%) |
| Mar 2017 | - | -$9.27 M(+77.8%) | -$28.61 M(+17.4%) |
| Dec 2016 | -$24.37 M(+104.5%) | -$5.21 M(-24.3%) | -$24.37 M(+108.2%) |
| Sep 2016 | - | -$6.88 M(-4.9%) | -$11.71 M(+10.9%) |
| Jun 2016 | - | -$7.24 M(+43.8%) | -$10.55 M(+8.4%) |
| Mar 2016 | - | -$5.03 M(-167.6%) | -$9.73 M(-14.6%) |
| Dec 2015 | -$11.92 M(-41.5%) | $7.45 M(-230.0%) | -$11.40 M(-56.8%) |
| Sep 2015 | - | -$5.73 M(-10.7%) | -$26.37 M(+1.0%) |
| Jun 2015 | - | -$6.42 M(-4.2%) | -$26.11 M(+9.2%) |
| Mar 2015 | - | -$6.70 M(-10.8%) | -$23.91 M(+17.2%) |
| Dec 2014 | -$20.39 M(+16.3%) | -$7.51 M(+37.3%) | -$20.39 M(-2.3%) |
| Sep 2014 | - | -$5.47 M(+29.6%) | -$20.88 M(+1.2%) |
| Jun 2014 | - | -$4.22 M(+32.5%) | -$20.62 M(+11.1%) |
| Mar 2014 | - | -$3.19 M(-60.2%) | -$18.56 M(+8.5%) |
| Dec 2013 | -$17.54 M(+146.7%) | -$8.00 M(+53.2%) | -$17.11 M(+87.8%) |
| Sep 2013 | - | -$5.22 M(+141.6%) | -$9.11 M(+134.1%) |
| Jun 2013 | - | -$2.16 M(+24.8%) | -$3.89 M(+124.8%) |
| Mar 2013 | - | -$1.73 M | -$1.73 M |
| Dec 2012 | -$7.11 M | - | - |
FAQ
- What is Leap Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Leap Therapeutics?
- What is Leap Therapeutics annual EBITDA year-on-year change?
- What is Leap Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Leap Therapeutics?
- What is Leap Therapeutics quarterly EBITDA year-on-year change?
- What is Leap Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Leap Therapeutics?
- What is Leap Therapeutics TTM EBITDA year-on-year change?
What is Leap Therapeutics annual EBITDA?
The current annual EBITDA of LPTX is -$81.40 M
What is the all time high annual EBITDA for Leap Therapeutics?
Leap Therapeutics all-time high annual EBITDA is -$7.11 M
What is Leap Therapeutics annual EBITDA year-on-year change?
Over the past year, LPTX annual EBITDA has changed by -$27.02 M (-49.69%)
What is Leap Therapeutics quarterly EBITDA?
The current quarterly EBITDA of LPTX is -$18.35 M
What is the all time high quarterly EBITDA for Leap Therapeutics?
Leap Therapeutics all-time high quarterly EBITDA is $7.45 M
What is Leap Therapeutics quarterly EBITDA year-on-year change?
Over the past year, LPTX quarterly EBITDA has changed by -$8.04 M (-77.97%)
What is Leap Therapeutics TTM EBITDA?
The current TTM EBITDA of LPTX is -$64.04 M
What is the all time high TTM EBITDA for Leap Therapeutics?
Leap Therapeutics all-time high TTM EBITDA is -$1.73 M
What is Leap Therapeutics TTM EBITDA year-on-year change?
Over the past year, LPTX TTM EBITDA has changed by +$17.16 M (+21.14%)